BioAdvance News

Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339

By WebmasterSeptember 20, 2011November 1st, 2024No Comments

Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
Read more here

Previous PostFDA Accepts Filing of New Drug Application (NDA) for Yaupon's Proprietary Gel Formulation of Mechlorethamine Hydrochloride
Next PostYaupon Therapeutics, Inc. Secures $14.4 Million in Series D Financing